ABSI
Absci Corporation
$5.90
+2.61%
2026-05-08
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Key Fundamentals
Forward P/E
-8.05
EPS (TTM)
$-0.84
ROE
-62.5%
Revenue Growth (YoY)
-2.3%
Profit Margin
0.0%
Debt/Equity
2.80
Price/Book
4.03
Beta
2.38
Market Cap
$783.5M
Avg Volume (10D)
6.1M
Recent Breakout Signals
No recent breakout signals detected for ABSI.
Recent Price Range (60 Days)
60D High
$6.24
60D Low
$2.24
Avg Volume
4.2M
Latest Close
$5.90
Get breakout alerts for ABSI
Sign up for Breakout Scanner to receive daily notifications when ABSI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Absci Corporation (ABSI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABSI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABSI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.